Company / Return on Equity (ROE)
TherapeuticsMD, Inc. Return on Equity (ROE) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-35.1%
FY2024
5-year range
-136.0% / 318.7%
FY2020-FY2024
Trend
-111.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
TherapeuticsMD, Inc. reports negative total equity of -35.1% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-35.1% in FY2024 with a 5-year CAGR of +24.1%.
Improved from -136.0% to -35.1% over the past 4 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- +24.1pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 111.0% year-over-year.
- Peak return on equity (roe) was recorded in FY2023.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -35.1% | -111.0% |
| FY2023 | 318.7% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | -136.0% | -129.7% |
| FY2019 | -59.2% | +16.0% |
| FY2018 | -70.5% | +47.7% |
| FY2017 | -134.9% | -20.4% |
| FY2016 | -112.0% | -115.6% |
| FY2015 | -52.0% | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026